Join Rapid Medical for a virtual key opinion leader (KOL) event featuring Ronen Eckhouse, Co-Founder & CEO of Rapid Medical, alongside leading stroke experts Jeffrey Saver, MD (UCLA) and Shahram Majidi, MD (Mount Sinai), who will provide clinical perspectives on the evolving treatment paradigm in ischemic stroke.

The discussion will provide clinical perspectives on a major advancement in ischemic stroke treatment, including an overview of the new data from Rapid Medical’s DISTALS study evaluating the TIGERTRIEVER™ 13 platform. The first positive clinical results in the emerging medium vessel occlusion (MeVO) segment— featuring DISTALS study data on the TIGERTRIEVER™ 13.

TIGERTRIEVER™ is the only active thrombectomy device, engineered to adapt to patient anatomy, accelerate clot integration, and reduce stress on the brain during mechanical thrombectomy procedures. The DISTALS study represents the first randomized evidence demonstrating superiority of a device-based intervention over medical management in distal stroke, potentially expanding the treatable patient population and reshaping clinical practice. Management will also discuss implications for future treatment protocols and market expansion.

A live question and answer session will follow the formal presentations.